An unexpected role for caspase-2 in neuroblastoma

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Dorstyn, L ^a,b   Puccini, J ^a   Nikolic, A ^a   Shalini, S ^a   Wilson, C H ^a   Norris, M D ^c   Haber, M ^c   Kumar, S ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c University of New South Wales   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 2; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; HUMAN; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; METABOLISM; MORTALITY; MOUSE; NEUROBLASTOMA; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CASPASE 2; DISEASE MODELS, ANIMAL; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROBLASTOMA; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84906885515     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.342     Document Type: Article

References (59)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
2. Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer 2009; 9: 897-903.
3. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14: 10-22.
4. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75-86.
5. Ho LH, Read SH, Dorstyn L, Lambrusco L, Kumar S. Caspase-2 is required for cell death induced by cytoskeletal disruption. Oncogene 2008; 27: 3393-3404.
6. Dorstyn L, Puccini J, Wilson CH, Shalini S, Nicola M, Moore S et al. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. Cell Death Differ 2012; 19: 1288-1298.
7. Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. A tumor suppressor function for caspase-2. Proc Natl Acad Sci USA 2009; 106: 5336-5341.
8. Shalini S, Dorstyn L, Wilson C, Puccini J, Ho L, Kumar S. Impaired antioxidant defence and accumulation of oxidative stress in caspase-2-deficient mice. Cell Death Differ 2012; 19: 1370-1380.
9. Parsons MJ, McCormick L, Janke L, Howard A, Bouchier-Hayes L, Green DR. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. Cell Death Differ 2013; 20: 1174-1182.
10. Puccini J, Shalini S, Voss AK, Gatei M, Wilson CH, Hiwase DK et al. Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proc Natl Acad Sci USA 2013; 110: 19920-19925.
11. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
12. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008; 27: 1905-1915.
13. Prochownik EV, Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 2007; 6: 1024-1029.
14. Wolfer A, Ramaswamy S. Prognostic signatures, cancer metastasis and MYC. Cell Cycle 2010; 9: 3639.
15. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
16. Hynes NE, Lane HA. Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. J Mammary Gland Biol Neoplasia 2001; 6: 141-150.
17. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000; 19: 1647-1656.
18. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210-3223.
19. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-2995.
20. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17: 2264-2279.
21. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
22. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1259.
23. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008; 68: 9735-9745.
24. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 2011; 7: e1002135.
25. Norris MD, Burkhart CA, Marshall GM, Weiss WA, Haber M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 2000; 35: 585-589.
26. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006; 439: 95-99.
27. Teitz T, Inoue M, Valentine MB, Zhu K, Rehg JE, Zhao W et al. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res 2013; 73: 4086-4097.
28. Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M et al. PIDDosome-independent tumor suppression by Caspase-2. Cell Death Differ 2012; 19: 1722-1732.
29. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011; 103: 1236-1251.
30. Puccini J, Dorstyn L, Kumar S. Genetic background and tumour susceptibility in mouse models. Cell Death Differ 2013; 20: 964.
31. Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H et al. Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 2008; 61: 1098-1103.
32. Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C et al. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 2007; 43: 1467-1475.
33. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102: 731-736.
34. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCNamplified neuroblastoma. Nat Med 2010; 16: 1134-1140.
35. Kapeli K, Hurlin PJ. Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen- activated protein kinase pathway. J Biol Chem 2011; 286: 38498-38508.
36. Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N et al. Tumor development, growth characteristics and spectrum of genetic aberrations in the THMYCN mouse model of neuroblastoma. PLoS One 2012; 7: e51297.
37. Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA et al. Differential expression of myc family genes during murine development. Nature 1986; 319: 780-783.
38. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
39. Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009; 185: 203-211.
40. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005; 11: 4321-4330.
41. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997; 3: 1699-1706.
42. Jacobs JF, van Bokhoven H, van Leeuwen FN, Hulsbergen-van de Kaa CA, de Vries IJ, Adema GJ et al. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 2009; 9: 239.
43. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA 2012; 109: 19190-19195.
44. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13: 397-411.
45. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006; 66: 8139-8146.
46. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004; 131: 217-228.
47. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 405-414.
48. Ribatti D, Vacca A, Nico B, De Falco G, Giuseppe Montaldo P, Ponzoni M. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 2002; 38: 750-757.
49. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 2000; 14: 1390-1399.
50. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
51. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999; 18: 1177-1184.
52. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally downregulated expression in the mouse brain. Biochem Biophys Res Commun 1992; 185: 1155-1161.
53. Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme 1994Genes Dev 1994; 8: 1613-1626.
54. Pistritto G, Papaleo V, Sanchez P, Ceci C, Barbaccia ML. Divergent modulation of neuronal differentiation by caspase-2 and -9. PLoS One 2012; 7: e36002.
55. Kristiansen M, Ham J. Programmed cell death during neuronal development: the sympathetic neuron model. Cell Death Differ 2014; 21: 1025-1035.
56. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998; 12: 1304-1314.
57. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL et al. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 2002; 9: 832-841.
58. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM et al. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 2003; 95: 1394-1403.
59. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 2004; 101: 12664-12669.